Compares two home dialysis methods for people with kidney failure
Compares automated and manual home peritoneal dialysis in adults with end-stage kidney disease.
Plain-language title generated from the registry record
Registry title: Comparative Study of Prognosis and QOL Between APD-RPM and CAPD
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with end-stage kidney disease who have been on peritoneal dialysis for at least 3 months and have a fast peritoneal solute transfer rate.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Confirmed end-stage renal disease. A peritoneal balance test shows a rapid solute transfer rate (4-hour D/P creatinine value greater than 0.65).
- Earlier treatment
- Peritoneal dialysis for 3 months or longer. People who use icodextrin dialysate cannot join.
- Biomarker or test result
- 4-hour D/P creatinine value greater than 0.65 on the standard peritoneal balance test.
Main reasons for not taking part
- Planning a kidney transplant within 3 years
- Needs hemodialysis as well
- Severe heart or brain disease, such as heart failure NYHA grade III or above, or a heart attack or stroke within 3 months
- Serious liver disease, active cancer or HIV infection
- Peritonitis in the past 3 months
This trial only enrols participants on dialysis. The registry sentence this rests on: Be able to comply with the standard peritoneal dialysis treatment at home
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05738525, who can take part
Where in China
- Chinese PLA General HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese PLA General Hospital
- Trial code
- NCT05738525
- Record updated
- 22 June 2023
- Original description
This is an observational, multicenter, parallel control study, planning to enroll 750 eligible patients to receive automated peritoneal dialysis with remote patient management (APD-RPM) and continuous ambulatory peritoneal dialysis (CAPD). Patients will attend follow-up every 12 ± 1 weeks for a total of 156 weeks. This study aims to compare the effects of APD-RPM and CAPD treatment on the prognosis and quality of life.Read full original descriptionShow less
Comparative Study of Automated Peritoneal Dialysis With Remote Patient Management And Continuous Ambulatory Peritoneal Dialysis on the Prognosis and QOL in Peritoneal Dialysis Patients
This is an observational, multicenter, parallel control study, planning to enroll 750 eligible patients to receive automated peritoneal dialysis with remote patient management (APD-RPM) and continuous ambulatory peritoneal dialysis (CAPD). Patients will attend follow-up every 12 ± 1 weeks for a total of 156 weeks. This study aims to compare the effects of APD-RPM and CAPD treatment on the prognosis and quality of life.
Inclusion: Aged 18 years to 75 years; Confirmed diagnosis of end-stage renal disease; Standard peritoneal balance test shows rapid peritoneal solute transfer rate, defined as 4 hours D/P creatinine value greater than 0.65; Be able to comply with the standard peritoneal dialysis treatment at home; Peritoneal dialysis time 3 months and longer; Fully understand the study and have signed the informed consent.
Exclusion: Prepare for kidney transplantation within 3 years; Be allergic to components of peritoneal dialysis fluid; Complicated with severe cardio-cerebrovascular diseases such as congestive heart failure, grade III and above of NYHA classification, acute myocardial infarction within 3 months, malignant arrhythmia requiring treatment, dilated cardiomyopathy, acute cerebral infarction or acute cerebral hemorrhage within 3 months, etc; Active or treated residual malignant tumors, HIV infection; History of alcohol or drug (illegal drugs) abuse; Unable to continue CAPD due to ultrafiltration failure; Mental retardation or mental illness; Complicated with serious liver diseases, such as cirrhosis or acute liver injury [Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) 2 times greater the the normal]; Pregnant or lactating women at childbearing age who disagree to use effective contraceptives during the trial; Need combined treatment of hemodialysis; Patients who use icodextrin dialysate; Participation in other clinical trials in the past 3 months; Peritonitis in the past 3 months; Other situations decided by the investigator.